Secondary acute myeloblastic leukemia after adjuvant chemotherapy and radiotherapy in breast cancer: A case report

Abstract

A rising number of long-term survivors and potential long-term outcome related to the treatment is
one of the most important issue due to the advances of management in cancer. The development of
secondary malignancy has been reported in a number of cohorts. We present a case of breast cancer
patient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and a
half years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin and
cyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T) and radiotherapy. What
could be attributed to the occurrence of secondary leukemia in this patient will be discussed.